AIFF (Firefly Neuroscience) Common Stock : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Firefly Neuroscience Common Stock?

Firefly Neuroscience's quarterly common stock stayed the same from Sep. 2023 ($0.00 Mil) to Jun. 2024 ($0.00 Mil) but then increased from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($0.00 Mil).

Firefly Neuroscience's annual common stock stayed the same from . 20 ($0.00 Mil) to Dec. 2021 ($0.00 Mil) but then increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.02 Mil).

Firefly Neuroscience Common Stock Historical Data

The historical data trend for Firefly Neuroscience's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Firefly Neuroscience Common Stock Chart

Firefly Neuroscience Annual Data

Trend

Dec21

Dec22

Common Stock

0.02

Firefly Neuroscience Quarterly Data
	Dec21	Sep22	Dec22	Jun23	Sep23	Jun24	Sep24
Common Stock	Get a 7-Day Free Trial			0.02	-	-	-	-

Firefly Neuroscience Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Firefly Neuroscience Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Technology » Software » Firefly Neuroscience Inc (NAS:AIFF) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

150 King Street W, 2nd Floor, Toronto, ON, CAN, M5H 1J9

Website

https://www.fireflyneuro.com

Firefly Neuroscience Inc is an AI company developing innovative neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support better outcomes for people suffering from mental illnesses and cognitive disorders.